A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)

被引：1

作者：

Ho, A. L. ^{[1
]}

Adkins, D. R. ^{[2
]}

Hanna, G. J. ^{[3
]}

Bruce, J. ^{[4
]}

Ahn, M. J. ^{[5
]}

Docampo, L. Iglesias ^{[6
]}

Kang, H. ^{[7
]}

Wong, D. J. ^{[8
]}

Psyrri, A. ^{[9
]}

Gillison, M. ^{[10
]}

Brana, I. ^{[11
]}

Liu, Y. C. ^{[12
]}

Hsieh, C. Y. ^{[13
]}

Hong, M. H. ^{[14
]}

Zhang, Z. ^{[15
]}

Balsara, B. ^{[15
]}

Saunders, A. ^{[15
]}

Hernandez, A. Gasco ^{[15
]}

Dale, S. ^{[15
]}

Haddad, R. ^{[3
]}

机构：

[1] Mem Sloan Kettering Evelyn H Lauder Breast Ctr, Med, New York, NY USA

[2] Washington Univ, Oncol, Sch Med St Louis, St Louis, MO USA

[3] Dana Farber Canc Inst, Med Oncol, Boston, MA USA

[4] Univ Wisconsin, Med, Carbone Canc Ctr, Madison, WI USA

[5] Sungkyunkwan Univ, Hematol Oncol Dept, Samsung Med Ctr SMC, Sch Med, Seoul, South Korea

[6] Hosp Univ 12 Octubre, Serv Oncol, Madrid, Spain

[7] Univ Calif San Francisco, Dept Med, San Francisco, CA USA

[8] UCLA, Med, Hematol Oncol, David Geffen Sch Med, Los Angeles, CA USA

[9] Attikon Univ Hosp, Internal Med Med Oncol, Haidari, Greece

[10] Univ Texas MD Anderson Canc Ctr Houston, Med, Houston, TX USA

[11] Vall Hebron Univ Hosp, Mol Therapeut Res Unit, Barcelona, Spain

[12] Taichung Vet Gen Hosp, Med, Taichung, Taiwan

[13] China Med Univ Hosp, Med, Taichung, Taiwan

[14] Yonsei Univ, Severance Hosp, Med, Coll Med, Seoul, South Korea

[15] Kura Oncol Inc, Clin Dev, Boston, MA USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.041

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA47

引用

页码：S1286 / S1287

页数：2

共 50 条

[1] The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with HRAS mutations.
Haddad, Robert I.
Adkins, Douglas
Licitra, Lisa F.
Bruce, Justine Yang
Gillison, Maura L.
Ahn, Myung-Ju
Hsieh, Ching-Yun
Wang, Hung-Ming
Psyrri, Amanda
Machiels, Jean-Pascal H.
Balsara, Binaifer
Leoni, Mollie
Harrington, Kevin Joseph
Saba, Nabil F.
Ho, Alan Loh
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[2] The AIM-HN and SEQ-HN study: A pivotal study evaluating the efficacy of tipifarnib in patients with head and neck squamous cell carcinoma (HNSCC) with hras mutations (AIM-HN) and the impact of hras mutations on response to first line systemic therapies for HNSCC (SEQ-HN).
Haddad, Robert, I
Harrington, Kevin Joseph
Licitra, Lisa F.
Psyrri, Amanda
Saba, Nabil F.
Rajicic, Natasa
Balsara, Binaifer
Kurman, Michael R.
Scholz, Catherine Rose
Gualberto, Antonio
Ho, Alan Loh
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[3] Efficacy and safety of penpulimab plus anlotinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): A phase II study
Shi, Y-K.
Gao, L.
Tian, Y.
Chen, J.
Wang, J.
Bai, C.
Li, X.
Su, H.
Liu, Z.
ANNALS OF ONCOLOGY, 2021, 32 : S806 - S806
[4] A phase I/Ib study of lenvatinib and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Dunn, Lara
Ho, Alan Loh
Eng, Juliana
Michel, Loren S.
Fetten, James Vincent
Warner, Elizabeth
Kriplani, Anuja
Zhi, Wanqing Iris
Ng, Kenneth K.
Haque, Sofia
Pfister, David G.
Sherman, Eric Jeffrey
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[5] Phase II study of temsirolimus and erlotinib in patients (pts) with recurrent/metastatic (R/M), platinum-refractory head and neck squamous cell carcinoma (HNSCC)
Bauman, Julie E.
Arias-Pulido, Hugo
Lee, Sang-Joon
Considine, Michael
Fekrazad, M. Houman
Howard, Jason
Bishop, Justin A.
Olson, Garth T.
Jones, Dennie V.
Fertig, Elana J.
Chung, Christine H.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[6] Phase II trial evaluating axitinib for patients with uaresectable, recurrent, or metastatic (R/M) bead and neck squamous cell carcinoma (HNSCC)
Sacco, Assuntina Gesualda
Zhao, Lill
Carey, Thomas E.
Dobrosotskaya, Irina Y.
McHugh, Jonathan B.
Chepeha, Douglas Brian
Bradford, Carol Roasler
Wolf, Gregory T.
Prince, Mark E.
Moyer, Jeffrey
McKean, Erin Lynn
McLean, Scott A.
Malloy, Kelly M.
Spector, Matthew E.
Hogikyan, Norman D.
Urba, Susan
Ward, Brent
Worden, Francis P.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[7] Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
Tang, Patricia A.
Siu, Lillian L.
Chen, Eric X.
Hotte, Sebastien J.
Chia, Stephen
Schwarz, James K.
Pond, Gregory R.
Johnson, Caitlin
Colevas, A. Dimitrios
Synold, Timothy W.
Vasist, Lakshmi S.
Winquist, Eric
INVESTIGATIONAL NEW DRUGS, 2008, 26 (03) : 257 - 264
[8] A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
de Souza, Jonas A.
Davis, Darren W.
Zhang, Yujian
Khattri, Arun
Seiwert, Tanguy Y.
Aktolga, Serdal
Wong, Stuart J.
Kozloff, Mark F.
Nattam, Sreenivasa
Lingen, Mark W.
Kunnavakkam, Rangesh
Stenson, Kerstin M.
Blair, Elizabeth A.
Bozeman, Jeffrey
Dancey, Janet E.
Vokes, Everett E.
Cohen, Ezra E. W.
CLINICAL CANCER RESEARCH, 2012, 18 (08) : 2336 - 2343
[9] Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
Patricia A. Tang
Lillian L. Siu
Eric X. Chen
Sebastien J. Hotte
Stephen Chia
James K. Schwarz
Gregory R. Pond
Caitlin Johnson
A. Dimitrios Colevas
Timothy W. Synold
Lakshmi S. Vasist
Eric Winquist
Investigational New Drugs, 2008, 26 : 257 - 264
[10] Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).
Kim, E. S.
Kies, M. S.
Glisson, B. S.
Ginsberg, L. E.
Holsinger, F. C.
Burke, B. J.
Truong, M.
Tsao, A. S.
Hong, W. K.
Lippman, S. M.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 285S - 285S

← 1 2 3 4 5 →